This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
In fact, the preparation of rosuvastatin sodium salt, which may be an intermediate in the preparation of rosuvastatin calcium salt, may not be reproducible both in terms of yield and physical state, depending on reaction conditions and solvent evaporation , while the latter is difficult to control
International application WO 2005 / 23778 attempts to avoid said problem by extracting impurities from an aqueous solution of rosuvastatin sodium salt into a water-immiscible solvent without isolating rosuvastatin sodium salt, but by using C 1 -C 4 Alcohol as a reaction medium still presents the danger of transformation into specific impurities
That is, β-hydroxyacids are known to dehydrate in alcoholic alkaline solutions, possibly resulting in specific by-products after re-alkoxylation (see Scheme 1, where R and R 1 Independence means C 1 -C 5 Alkyl), O-alkyl derivatives of rosuvastatin, such as O-ethyl rosuvastatin
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
no. 1 approach
[0047] According to a first embodiment of the present invention, rosuvastatin C 1 -C 5 Alkyl ester, more preferably rosuvastatin tert-alkyl ester, most preferably rosuvastatin tert-butyl ester or rosuvastatin lactone in an organic nitrogenous base optionally containing an organic aprotic solvent such as THF and water Cleavage in , wherein alkyl represents methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, pentyl or tert-amyl.
[0048] The used organic nitrogenous base of the inventive method is selected from:
[0049] a) Guanidines of the following formula:
[0050]
[0051] where R 1 , R 2 , R 3 , R 4 and R 5 Each independently represents a hydrogen atom, a straight chain or a branched chain C 1 -C 6 Alkyl or C 1 -C 6 Cycloalkyl, or R 1 , R 2 , R 3 , R 4 and R 5 Each pair in independently represents the C connected to form a ring 1 -C 6 alkylene;
[0052] b) amidines of the following formula:
[0053]
[0054] where R 1 , R 2 , R 3...
Embodiment 1
[0099] Hydrolysis of rosuvastatin tert-butyl ester in aqueous amine solution
[0100] 7.5g rosuvastatin tert-butyl ester
[0101] 38ml demineralized water
[0102] 2-5 equivalents of amine
[0103] The reaction was stirred with water as solvent in an autoclave at 98°C-100°C for 1-4 hours. The reaction mixture was sampled and analyzed by HPLC ("High Pressure Liquid Chromatography") to determine the completion of the reaction. The results are shown in Table 1.
[0104] Table 1
[0105] amine
Embodiment 2
[0107] Hydrolysis of Rosuvastatin Lactone in Aqueous N-Methylcyclohexylamine
[0108] 0.5g rosuvastatin lactone
[0109] 0.5ml N-methylcyclohexylamine
[0110] 3.0ml demineralized water
[0111] The reaction was stirred with solvent at 90°C for 1 hour to form a clear solution and analyzed as described in Example 1. HPLC analysis showed that the starting lactone was completely consumed.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
A pure amorphous form of rosuvastatin calcium having purity of more than 99.5%, preferably a purity of more than 99.8%, more preferably a purity of more than 99.9% as determined by HPLC area percentage, and free from any traces of alkali metal impurities is disclosed. A process of preparing said pure amorphous form of rosuvastatin calcium is disclosed, which comprises hydrolysis of C1-C5 alkyl esters of rosuvastatin, preferably terf-butyl ester of rosuvastatin, with an organic nitrogen base, e.g. guanidines, amidines, amines and quaternary ammonium hydroxides, in the presence of water, optionally containing aprotic solvent, following the conversion of thus obtained rosuvastain salt with a source of calcium to desired rosuvastatin calcium, which is then isolated. An alternative process is disclosed, which comprises the conversion of numerous novel ammonium salts of rosuvastatin, preferably tert-octylammonium salt of rosuvastatin, with the source of calcium to desired commercial rosuvastatin calcium. Rosuvastatin calcium is HMG CoA reductase, useful in the treatment of hyperlipidemia, hypercholesterolemia and atherosclerosis.
Description
technical field [0001] The present invention relates to a method for preparing amorphous rosuvastatin calcium substantially free of alkali metal impurities via rosuvastatin ammonium salt as an intermediate compound. Background technique [0002] Rosuvastatin is (+)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonyl) administered as calcium salt in therapy Amino)pyrimidin-5-yl]-(3R,5S)-dihydroxy-(E)-heptenoic acid is the generic name of a commercial drug, and represented by Formula 1 below, said compound is 3-hydroxy-3- The inhibitor of methylglutaryl-coenzyme A reductase (HMG CoA reductase) can be used for treating hyperlipidemia, hypercholesterolemia and atherosclerosis. The synthesis of rosuvastatin and rosuvastatin calcium was first described in EP-B-521471 patent; in the last two steps of the whole synthesis, it is obtained as follows: in a polar solvent such as ethanol, in the presence of a base such as hydrogen In the presence of sodium oxide, hydrolysis ...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more